gastroenterology
Coeliac disease

Oral budesonide disappoints in first RCT for coeliac disease

An Australian pilot study has failed to demonstrate a benefit on mucosal healing from oral budesonide, in addition to a gluten-free diet, in patients with newly diagnosed coeliac disease. The RCT compared mucosal healing in biopsy specimens at 8 weeks and 52 weeks in 37 patients treated with either 9 mg/day budesonide for 8 weeks, ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic